 |
 |

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—Reply
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In Reply: Drs FitzGerald, Patrono, and Hawkey write that review papers they authored were inappropriately included in the Table in our article, explaining that their articles were independently authored without discussion of their content with Merck before publication. The Table, as stated in its legend and in the text of the article, includes articles identified from internal documents,1-2 as well as other articles by investigators identified within internal documents. Articles by such investigators were found by searching MEDLINE, as we described. All of these articles were examined to better understand patterns of disclosure, as we believed that either their mention within internal documents or the mention of specific investigators suggested that Merck was aware of the publication and perhaps had provided support for the project. Correspondence with Merck, acknowledged by FitzGerald and Patrono, led to the identification of their articles using MEDLINE. To our knowledge, these articles were not discussed . . . [Full Text of this Article]
Joseph S. Ross, MD, MHS
joseph.ross@mssm.edu Department of Geriatrics and Adult Development Mount Sinai School of Medicine New York, New York
David S. Egilman, MD, MPH
Department of Community Health Brown University School of Medicine Providence, Rhode Island
Harlan M. Krumholz, MD, SM
Department of Medicine Yale University School of Medicine New Haven, Connecticut
RELATED LETTERS
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Kent R. Johnson and Marissa N. D. Lassere
JAMA. 2008;300(8):900.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Garret A. FitzGerald
JAMA. 2008;300(8):900-901.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Carlo Patrono
JAMA. 2008;300(8):901.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Christopher J. Hawkey
JAMA. 2008;300(8):901.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Steven Ferris, Douglas Galasko, and Louis Kirby
JAMA. 2008;300(8):901-902.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Richard Balon
JAMA. 2008;300(8):902.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Serban-Dan Costa
JAMA. 2008;300(8):902-903.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Hervé Maisonneuve
JAMA. 2008;300(8):903.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Hean T. Ong and Jin S. Cheah
JAMA. 2008;300(8):903-904.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Peter A. Lachenbruch and Ronald Wasserstein
JAMA. 2008;300(8):904.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—Reply
Bruce M. Psaty and Richard A. Kronmal
JAMA. 2008;300(8):904.
EXTRACT
| FULL TEXT
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—Reply
Catherine D. DeAngelis and Phil B. Fontanarosa
JAMA. 2008;300(8):905-906.
EXTRACT
| FULL TEXT
|